Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11408190 | 0.96 | HTT (0.50) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL12154218 | 0.94 | KMT2A (0.61) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL20045170 | 0.94 | KMT2A (0.61) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL24605352 | 0.88 | KMT2A (0.68) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL27947111 | 0.88 | KMT2A (0.68) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL12370833 | 0.88 | KMT2A (0.68) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL2741099 | 0.88 | KMT2A (0.68) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL12012965 | 0.88 | KMT2A (0.51) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL17059002 | 0.88 | KMT2A (0.54) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL20443893 | 0.88 | KMT2A (0.54) | HTTKMT2ASMN1; SMN2TDP1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120274888-A1 | OPTICALLY ANISOTROPIC SUBSTANCE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-11-01 | — | — | US | disclosed |
| US-8048496-B2 | Polymerizable liquid crystal compound, liquid crystal composition and polymer | JNC CORPORATION (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20100297367-A1 | OPTICALLY ANISOTROPIC SUBSTANCE | CHISSO CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100096591-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND POLYMER | CHISSO CORPORATION | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100096591-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND POLYMER | PKN1, ZYX, OXER1 | HTT 3468/4885KMT2A 1370/4885SMN1; SMN2 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.